Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Return on Equity (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Return on Equity for 12 consecutive years, with 0.13% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Equity rose 38.0% to 0.13% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.13%, a 38.0% increase, with the full-year FY2020 number at 0.06%, down 178.0% from a year prior.
  • Return on Equity was 0.13% for Q3 2025 at Theravance Biopharma, up from 0.07% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 13.83% in Q3 2022 to a low of 0.33% in Q1 2025.
  • A 5-year average of 1.3% and a median of 0.13% in 2025 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: soared 1319bps in 2022, then tumbled -1399bps in 2023.
  • Theravance Biopharma's Return on Equity stood at 0.64% in 2021, then skyrocketed by 229bps to 2.09% in 2022, then plummeted by -108bps to 0.16% in 2023, then tumbled by -88bps to 0.31% in 2024, then surged by 142bps to 0.13% in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Return on Equity are 0.13% (Q3 2025), 0.07% (Q2 2025), and 0.33% (Q1 2025).